MLP SE

  • WKN: 656990
  • ISIN: DE0006569908
  • Land: Deutschland

Nachricht vom 21.04.2021 | 18:10

MLP SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

MLP SE
21.04.2021 / 18:10
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

HanseMerkur Krankenversicherung auf Gegenseitigkeit, Hamburg, Germany notified us on April 20, 2021 pursuant to Section 43 (1) WpHG in connection with exceeding the threshold of 10% of the voting rights on April 16, 2021 as follows:

1. the acquisition represents a financial investment with the aim of asset growth and ultimately serves to generate trading profits.

2. depending on individual company parameters of the issuer, the notifying party intends to acquire further shares - and thus voting rights - within the next 12 months in order to expand the financial investment.

3. Influence on the composition of administrative, management and supervisory bodies is sought if and to the extent that this appears expedient to promote the financial objectives pursuant to no. 1 above.

4. if and to the extent that this appears reasonable in order to promote the financial objectives pursuant to No. 1 above, a change in the dividend policy will be sought, which may have an indirect effect on the ratio of equity to debt financing.

 

The acquisition was made from own funds.



21.04.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021